Title: Executive Director & Chief Scientific Officer
Workplace: ChristianaCare Gene Editing Institute & CorriXR Therapeutics
Alma Maters: Rutgers University, Southern Illinois University, University of Florida School of Medicine
Boards: Philadelphia-Israel Chamber of Commerce, Gene & Genome Editing
What’s something interesting that is not on your resume? “I have had the honor to watch both my sons excel at baseball and I had the privilege of watching and coaching them throughout their careers. One was invited to play for the St. Louis Cardinals.”
As one of the nation’s foremost researchers on the gene-editing technology known as CRISPR for the last three decades, Eric Kmiec has brought attention to Delaware from the wider biopharmaceutical industry. The former University of Delaware professor partnered in 2015 with the state’s largest health care system, ChristianaCare, to launch the Gene Editing Institute to further research into the potential to overcome drug resistance in solid tumors. Its programs for treating cancers of the lung, head and neck, and esophageal cancer are now advancing through the U.S. Food & Drug Administration approval process toward the clinic. In 2022, he spun out some of the institute’s most promising work in a new startup, CorriXR Therapeutics, that could be a major job creator of the future.
